Crisaborole Brand Name– EUCRISA

What is Crisaborole

Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

Because crisaborole is administered topically, it avoids the gastrointestinal side effects that are associated with apremilast, an orally administered PDE-4 inhibitor. The most commonly reported adverse event with crisaborole is application site pain, which frequently develops after the first dose and resolves within 1 day.

Approval was based on the results of 2 double-blinded, vehicle-controlled trials involving 1,522 patients (ages 2 to 79 years) with mild to moderate atopic dermatitis.

The primary endpoint, defined as an Investigator’s Static Global Assessment score of clear (0) or almost clear (1) with a 2-grade or greater improvement from baseline, was achieved by more crisaborole-treated patients (31.4% to 32.8%) than those receiving vehicle ointment (18% to 25.4%).

In addition, the time to reach the primary endpoint occurred earlier in patients treated with crisaborole than in those treated with the vehicle.


  • atopic dermatitis

For the treatment of mild to moderate atopic dermatitis

Side Effects

  1. contact dermatitis
  2. skin irritation
  3. urticaria

Monitoring Parameters

  • laboratory monitoring not necessary


  • breast-feeding
  • ocular exposure
  • ophthalmic administration
  • pregnancy
  • vaginal administration


There are no drug interactions associated with Crisaborole products.


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top